Skip to main content
HairCited

Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors.

Caiwei Zheng, Antonella Tosti
Review Dermatologic clinics 2021 22 sitasi
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D34053594'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Jenis Studi
Review
Populasi
patients with aa experience significant regrowth
Intervensi
Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors. 70%
Pembanding
None
Luaran Utama
None
Arah Efek
Positive
Risiko Bias
Unclear

Abstract

Alopecia areata (AA) is a chronic, relapsing, autoimmune disorder characterized by patchy nonscaring hair loss. Although the pathogenesis of alopecia areata is not yet completely elucidated, loss of immune privilege in anagen stage hair follicles is widely accepted to play a key role. Several cytokines that depend on Janus kinase signaling have been identified to be involved in AA, including interleukin (IL)-2, IL-7, IL-15, IL-21, and interferon-γ, making Janus kinase inhibitors an attractive therapeutic target. Available information indicates that about 70% of patients with AA experience significant regrowth, but interruption of treatment is associated with disease recurrence.

TL;DR

Information indicates that about 70% of patients with alopecia areata experience significant regrowth, but interruption of treatment is associated with disease recurrence, making Janus kinase inhibitors an attractive therapeutic target.

Used In Evidence Reviews

Similar Papers